Who Owns Medexus Pharma Company?

Medexus Pharma Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Really Controls Medexus Pharma?

Unraveling the ownership of Medexus Pharma is key to understanding its future. Knowing who owns Medexus is crucial for investors and stakeholders alike. This knowledge illuminates the company's strategic direction and potential for growth in the competitive pharmaceutical landscape. Discover the key players shaping the future of this Canadian-based specialty pharmaceutical company.

Medexus Pharma, a publicly traded company, has a fascinating ownership structure that influences its focus on therapeutic areas like auto-immune diseases. Understanding the dynamics of Medexus ownership, from its early days to its current major shareholders, provides valuable insights. Explore the Medexus Pharma SWOT Analysis to gain a deeper understanding of the company's strengths and weaknesses, influenced by its ownership and strategic direction. This analysis will also touch on Medexus executives, Medexus investors, and the overall Medexus stock performance.

The origins of Medexus Pharma trace back to 2004, when Ken d'Entremont established the company. Ken d'Entremont has played a pivotal role in the company's leadership, holding the positions of Chief Executive Officer and Director since December 17, 2018.

Before his current roles, d'Entremont founded and led Medexus Inc. from its inception in 2000 until its acquisition. He served as President, Chief Executive Officer, and Chairman of the board of directors of Medexus Inc. during that period.

The available information does not provide specifics on the initial equity distribution or shareholding percentages of the founders at the company's start. Details regarding early investors, angel investors, or any initial agreements such as vesting schedules or founder exits are also not available in the provided search results. Information about the company's early ownership structure is limited.

Key Points on Founders and Early Ownership

Understanding the early ownership structure is crucial for assessing the company's trajectory. While the exact details of the initial ownership structure of Medexus Pharma are not available, the role of Ken d'Entremont as founder and CEO is well-documented.

• Ken d'Entremont founded Medexus Pharma in 2004.
• He has been the CEO and a Director since December 17, 2018.
• Prior to this, he founded and led Medexus Inc. from 2000.
• Specifics on early investors and equity splits are not available in the provided data.

Medexus Pharma SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Medexus Pharmaceuticals Inc., a publicly traded entity, has a market capitalization of approximately $69.5 million as of June 13, 2025. The company has around 32.3 million shares outstanding. Its shares are listed on the Toronto Stock Exchange (TSX: MDP) and the OTCQX (OTCQX: MEDXF). Understanding the ownership structure is crucial for investors and stakeholders interested in Medexus Pharma, as it influences strategic decisions and financial performance. The company's stock performance and investor relations are directly impacted by its ownership dynamics.

In January 2025, Medexus completed a public offering, issuing 7,500,000 common shares at C$4.00 each. This raised gross proceeds of C$30 million (approximately $20.9 million US gross, or $19.7 million US net proceeds before expenses). These funds were earmarked for working capital, business development, and to repay a US$2.5 million credit from medac and a portion of a milestone payment. This offering significantly impacted the company's capital structure and provided resources for growth initiatives. This is a key aspect of understanding Competitors Landscape of Medexus Pharma.

As of June 10, 2024, Perritt MicroCap Opportunities Fund Investor Class (PRCGX) was the only institutional owner and shareholder, holding a total of 130,100 shares. Other major shareholders include Goodwood Inc. The ownership structure of Medexus Pharma is subject to change, with institutional investors and major shareholders playing a significant role in the company's direction. Understanding the ownership structure is critical for investors and anyone tracking Medexus Pharma's performance.

Ownership Insights for Medexus Pharma

Medexus Pharma's ownership structure involves institutional investors and major shareholders. The company's stock is traded on the TSX and OTCQX. The recent public offering in January 2025 raised significant capital for the company.

• Medexus Pharma is a publicly traded company.
• Major shareholders include institutional investors and Goodwood Inc.
• The company completed a public offering in January 2025.
• The company's market capitalization is approximately $69.5 million as of June 13, 2025.

Medexus Pharma PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The current board of directors of Medexus Pharma consists of seven members. As of September 19, 2024, the board includes Ken d'Entremont, Harmony Garges, Benoit Gravel, Michael Mueller, Stephen Nelson, Nancy Phelan, and Menassie Taddese. Michael Mueller holds the position of Independent Chairman, while Ken d'Entremont serves as CEO and a Director. The average tenure of the board members is approximately 6.7 years.

Understanding the structure of Medexus Pharma's leadership is important for those interested in Medexus Pharma's target market. The board's composition and the voting power of shareholders directly influence the company's strategic decisions and overall direction. This information is crucial for investors and stakeholders evaluating the company's governance and performance.

Regarding voting rights, each share of Medexus Pharma's common stock is entitled to one vote at the Annual Meeting. Directors are elected based on a plurality of votes cast, and stockholders cannot cumulate their votes. Votes withheld from a director nominee and broker non-votes do not affect the outcome. As of December 31, 2024, there were 24,702,253 common shares outstanding. Ken d'Entremont's direct ownership is 4.61% of the company's shares, valued at approximately $3.20 million USD.

Voting Results from the 2024 Annual Meeting

At the Annual Meeting on September 19, 2024, all director nominees were re-elected, and other company proposals were approved.

• Ken d'Entremont received 99.02% of votes for and 0.98% against.
• Michael Mueller received 99.01% for and 0.99% against.
• Nancy Phelan received 98.66% for and 1.34% against.
• PricewaterhouseCoopers LLP was appointed as the company's auditors with 99.32% votes for.

Medexus Pharma Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

In recent years, significant developments have reshaped the ownership landscape of Medexus Pharma. A notable event was the public offering in January 2025, where the company issued 7,500,000 common shares at C$4.00 each. This raised approximately C$30 million in gross proceeds, which were earmarked for working capital, general corporate purposes, and the repayment of debt.

This offering, along with other financial activities, has influenced the company's share structure. The total shares outstanding increased by 31.9% over the past year, indicating a dilution of shares for existing Medexus investors. This dilution is a crucial factor for investors to consider when evaluating their holdings in Medexus stock.

Leadership changes have also been part of the recent trends. Brendon Buschman was appointed as Chief Financial Officer on June 28, 2024, succeeding Marcel Konrad. Additionally, Richard Labelle was appointed Chief Operating Officer, a new position, on June 24, 2024. These executive appointments are critical as they can influence the strategic direction and operational efficiency of the company, affecting the perspectives of those who own Medexus.

Ownership Structure

Understanding the ownership structure is key for Medexus investors. Knowing who the major shareholders of Medexus Pharma are provides insights into the company's strategic direction and stability. This information helps in assessing the potential impact of ownership changes on the company's future.

Financial Performance

Medexus Pharma's financial reports show a mixed picture. While revenue increased to $113.1 million in fiscal year 2024, the company still reported a net loss. Examining these financial reports provides a clearer view of the company's financial health and potential risks.

Stock Dilution

The increase in outstanding shares by 31.9% in the past year is a significant factor for Medexus investors. This dilution can affect the share price and the value of existing holdings. It is important for investors to monitor the company's share structure.

Executive Appointments

The appointment of new executives, such as the CFO and COO, can signal changes in strategy and operations. These changes can influence investor confidence and the overall direction of the company. Investors should watch these key personnel changes.

Medexus Pharma Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs